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Currently, there are no worldwide licensed vaccines for Rift Valley fever (RVF) that are both safe
and effective. Development and evaluation of vaccines, diagnostics and treatments depend on the
availability of appropriate animal models. Animal models are also necessary to understand the
basic pathobiology of infection. Here, we report the use of an inbred MBT/Pas mouse model that
consistently reproduces RVF disease and serves our purpose for testing the efficacy of vaccine
candidates; an attenuated Rift Valley fever virus (RVFV) and a recombinant RVFV–capripoxvirus.
We show that this model is relevant for vaccine testing.
INTRODUCTION
Rift Valley fever (RVF) is an arthropod-borne zoonotic
disease caused by RVF virus (RVFV), a member of the
genus Phlebovirus of the family Bunyaviridae (Elliott et al.,
2000). RVFV is maintained in the environment in an
enzootic vertebrate–mosquito cycle. The Aedes and Culex
mosquito genera are its main vectors even though other
arthropods may play a role in its spread (Fontenille et al.,
1998; Gerdes, 2004).
RVFV causes significant morbidity and mortality among
sheep, goat, cattle and humans. Mortality is extremely high
in young animals, causing sweeping abortion storms and
mortality ratios of approximately 100% among neonatal
animals and of 10–20% among adult ruminant live-
stock (especially sheep and cattle) (Coetzer, 1977, 1982;
Easterday, 1965). The disease in humans is generally mild,
however, in 1–2% of affected individuals, RVFV infections
can progress to more severe disease including fulminant
hepatitis, encephalitis, retinitis, blindness or a haemor-
rhagic syndrome (Al-Hazmi et al., 2003; McIntosh et al.,
1980). RVF outbreaks are considered as a significant threat
for endemic areas where mosquitoes are present in
abundance and where direct contact with infected animals
is frequent. Originally occurring in most of sub-Saharan
Africa, in recent years the virus has spread to northern
Africa and to Saudi Arabia and Yemen (Meegan et al.,
1979; Shoemaker et al., 2002) where it causes recurrent
outbreaks of large socio-economic impact. Introduction of
RVFV in non-endemic areas such as Europe would have
devastating consequences (Mandell & Flick, 2010).
In the face of expansion of the disease, currently, there are
no RVFV vaccines approved for general use in humans.
Several vaccines have been developed for use in livestock
with either a lack of efficacy or generating substantial side
effects especially in pregnant animals (Caplen et al., 1985;
Smithburn, 1949; Vialat et al., 1997). In the last decade,
progress has been made in the development of novel
experimental vaccines (Ikegami & Makino, 2009). Since the
development of an attenuated vaccine based on the
Smithburn strain (Smithburn, 1949), several alternative
attenuated vaccines have been studied: (i) clone 13 that
carries a natural large deletion in the gene encoding the
non-structural NSs protein (Dungu et al., 2010; Vialat et al.,
2000); (ii) the mutagenized MP 12 (Morrill et al., 1997;
Saluzzo & Smith, 1990); (iii) VLP (virus-like particle)-
based vaccines (de Boer et al., 2010; Mandell et al., 2010;
Na¨slund et al., 2009); (iv) nucleocapsid subunit vaccines
(Jansen Van Vuren et al., 2010, 2011); and (v) viral vector-
based vaccines (Heise et al., 2009; Holman et al., 2009;
Kortekaas et al., 2010a, 2010b; Papin et al., 2011; Soi et al.,
2010; Wallace & Viljoen, 2005; Wallace et al., 2006).
The medium (M) RNA segment of the RVFV genome
encodes the viral glycoproteins Gn and Gc that are the
main targets of protective immunity (Collett et al., 1985;
Kakach et al., 1988). When expressed by a recombinant
The GenBank/EMBL/DDBJ accession number for the sequence
reported in this paper is Q380200.
Journal of General Virology (2012), 93, 1456–1464 DOI 10.1099/vir.0.042754-0
1456 042754 G 2012 SGM Printed in Great Britain
Downloaded from www.microbiologyresearch.org by
IP:  137.108.70.7
On: Thu, 22 Dec 2016 19:16:45
vaccinia virus, they induce neutralizing antibodies and
protective immunity to RVF in mice (Collett et al., 1987)
and baboons (Papin et al., 2011). Attenuated strains of
lumpy skin disease virus (LSDV) and sheep pox virus
(SPV), both members of the genus Capripoxvirus have been
used effectively as vaccines for many years (Kitching et al.,
1987). Moreover, they have also been developed as vectors
for multivalent recombinant vaccines against livestock
diseases, such as rinderpest, Peste des Petits ruminants and
RVF (Berhe´ et al., 2003; Diallo et al., 2002; Ngichabe et al.,
1997, 2002; Romero et al., 1993; 1994; Soi et al., 2010;
Wallace & Viljoen, 2005; Wallace et al., 2006).
Several animal models of RVFV infection have been
described to better understand the nature of key patho-
genesis’ processes applicable to the development and
testing of vaccines and therapeutic agents (Ross et al.,
2012). RVFV is virulent in a number of species, including
rodents, livestock species (sheep, goats and cattle) and non-
human primates (NHP), with clinical signs ranging from
absent or mild reactions to fever and death in the most
susceptible animals. The existing NHP model for RVF
utilizes an intravenous exposure route in rhesus macaques
(Macaca mulatta). However, severe disease in these animals
is infrequent and large cohorts are needed to observe
significant morbidity and mortality. The common mar-
mosets (Callithrix jacchus) are more susceptible to RVFV
than rhesus macaques and experienced higher morbidity,
mortality, viraemia, and marked aberrations in haemato-
logical and biochemical values displaying signs of haemor-
rhagic manifestations and neurological impairment (Smith
et al., 2012). Ethical issues regarding the use of primates
and the limitations to their access could, however, be
considered as major drawbacks for their use as RVF
models. In contrast, hamsters and rats are highly
susceptible to RVFV infection and commonly handled in
experimental animal facilities (Findlay, 1932; Findlay &
Daubney, 1931; Peters & Linthicum, 1994). Nonetheless, a
variation in the susceptibility was demonstrated to be
linked to a dominant gene in the rat model (Anderson
et al., 1987, 1991; Ritter et al., 2000). The hamster model
has relied mainly on experimental infection with the Punta
Toro bunyavirus (Anderson et al., 1990; Fisher et al., 2003)
with only hepatitis and no encephalitis as the dominant
pathological feature. In addition, gerbils infected with
RVFV reportedly develop uniformly fatal encephalitis in
the absence of significant extraneural lesions (Anderson
et al., 1988). Mice, prime organisms of choice for modelling
human disease are known to be highly susceptible to
infection with RVFV by subcutaneous (s.c.) or intraper-
itoneal (i.p.) injection leading to fulminant hepatitis and a
late-developing encephalitis (Findlay & Daubney 1931;
Digoutte & Peters, 1989; Mims, 1956). However, an
influence of genetic factors could not be demonstrated in
a large survey of 34 classical inbred laboratory mouse
strains (Peters & Anderson 1981). Recently, the MBT/Pas
inbred strain of mice was shown to exhibit an extreme
susceptibility to experimental infection with the virulent
strain RVFV ZH548. A failure to induce, in due course, a
complete innate immune response to RVFV was proposed
to be instrumental in their susceptibility to RVF (do Valle
et al., 2010). This defect seems to be selective, since MBT/
Pas mice were shown to be resistant to infection with either
West Nile virus or influenza virus, in conditions where
classical inbred mouse strains die (do Valle et al., 2010).
The present investigation aimed at demonstrating that the
MBT/Pas mouse model is suitable for the evaluation of the
protective ability of vaccine candidates. Two vaccines were
tested: the naturally attenuated clone 13 and a recombinant
LSDV-vectored vaccine candidate, expressing RVFV gly-
coproteins.
RESULTS
Reproduction of RVF pathology in inbred MBT/
Pas mice
To evaluate the susceptibility and pathology induced by
RVFV in wild-derived MBT/Pas mice, 6-week-old females
were inoculated via the i.p. route with 100 p.f.u. of the
virulent strain ZH548, a human isolate from the Egyptian
outbreak in 1977–1978 (El-Akkad, 1978). Mortality was
monitored daily for 2 weeks. An extreme susceptibility to
RVFV was observed. Indeed, all MBT/Pas mice died within
4 days post-infection.
Expression of RVFV glycoproteins and
characterization of the rCpoxNSmGn
recombinant virus
The expression of RVFV proteins in lamb testis (LT) cells
(OA3.Ts) infected with the recombinant rCpoxNSmGn
was detected by immunofluorescence assay (IFA) (Fig. 1).
A negative control consisted of OA3.Ts cells infected with
the wild-type KS-1 strain. Recombinant poxviruses were
then generated and selected in the presence of the
Escherichia coli xanthine-guanine phosphoribosyltransfer-
ase gene (gpt) selection medium containing mycophenolic
acid, as described previously (Romero et al., 1993). A PCR
assay performed directly on DNA extracted from the viral
supernatant and targeting the thymidine kinase (TK) gene
(Perrin et al., 2007) failed to detect the KS-1 parental virus,
thus confirming the purity of the recombinant viruses.
Survival of inbred MBT/Pas mice conferred by the
two vaccines
To evaluate the immunogenicity of the rCpoxNSmGn and
clone 13 vaccines and their ability to protect against RVF,
two independent inbred MBT/mice experiments were
carried out and the survival/mortality rates and the virus
replication after virulent RVFV challenge were evaluated.
In the first experiment, two groups of 12 mice inoculated at
day 0 via the i.p. route with either clone 13 or culture
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medium were challenged 31 days later with the virulent
ZH548 strain. In each group, four animals were sacrificed
at days 28 and 32 and their spleens were removed for
analysis of cell-mediated immunity. Therefore, survival
after challenge was observed in the four remaining mice. In
the negative controls that received the culture medium,
three of the four mice died, respectively, at days 3, 4 and 5,
whereas all four mice of the clone 13 group were still alive
at day 14 post-challenge. RVFV neutralizing antibody titres
were measured by the RVFV neutralization test (VNT)
assay. High antibody responses to RVFV were detected at
day 28 post-immunization with titres higher than 1 : 80 in
all 12 animals inoculated with clone 13.
The second experiment comprised three groups of inbred
MBT/Pas mice (12 mice per group), a group inoculated
twice 3 weeks apart, with the recombinant rCpoxNSmGn, a
negative-control group and a group inoculated with clone
13 as in the first experiment. At days 0 and 21, mice were
inoculated with either a suspension of 106.9 TCID50 of the
rCpoxNSmGn RVFV recombinant construct or the nega-
tive-control recombinant capripox–haemagglutinin of the
Peste des Petits ruminants virus (HPPR) vaccine (negative-
control group), the suspension being administered via the
three routes all together: the intramuscular (i.m.), i.p. and
s.c. routes. The third group injected at day 0 intraperitone-
ally with 104 p.f.u. of clone 13 was used as a positive control.
All the animals were challenged at day 32 via the i.p. route
with 100 p.f.u. of the RVFV ZH548. In the negative-control
group, the four animals died within 5 days post-challenge:
one mouse succumbed, respectively, at days 3 and 5 and two
died at day 4. Out of four mice in the group vaccinated with
rCpoxNSmGn RVFV recombinant construct, only one died
at day 6 (Table 1). As indicated in Table 1, neutralizing
antibodies against RVFV with titres ranging from 5 to 30
were detected at day 28 (3 days prior to challenge) for six of
eight mice of the rCpoxNSmGn RVFV group and for five of
five mice of the clone 13 group. As expected, no neutralizing
antibodies were detected in the irrelevant recombinant
capripox–HPPR group. In contrast, rCpoxNSmGn elicited a
significant (Mann–Whitney U test; P,0.05), but moderate
neutralizing antibody response, which was, however, slightly
lower than the strong seroconversion (titres ranging from 80
to 320) that was observed for the clone 13 group.
Cell-mediated immunity
Lymphocyte proliferation was monitored at day 33, 2 days
after the challenge in the second experiment. A significant
difference was observed for the four animals included in the
rCpoxNSmGn RVFV group and for the four animals of the
clone 13 group compared with the irrelevant recombinant
capripox–HPPR control group (Fig. 2) for both subpopula-
tions CD4 (Fig. 2a) and CD8 (Fig. 2b) (Mann–Whitney U
test; P,0.05).
DISCUSSION
The changes following globalization, climate change and
the opening of previously closed ecosystems have consid-
erably modified the pattern of endemic or enzootic
infectious diseases and contributed to the emergence of
new agents that are pathogenic for humans and domestic
animals (Lovejoy, 2008; Morand & Gue´gan, 2008). In this
context, vaccination undoubtedly remains the most cost-
effective means of prevention and control by improving
health and protecting public health, and even eradicating
these infections. A comprehensive review identified 1415
species of infectious organisms known to be pathogenic to
humans, including 217 viruses and prions (Cleaveland
et al., 2001; Pastoret, 2009). Out of these, 868 (61%) were
classified as zoonotic and 175 pathogenic species were
considered to be associated with emerging diseases. Of 175
emerging pathogens of this group, 132 (75%) were
zoonotic (Slingenbergh et al., 2004) including RVFV.
Several animal models of RVFV infection have been
developed in order to reproduce natural infection in an
experimentally controlled system. The wild-derived MBT/
Pas inbred strain has already been demonstrated as a
suitable model for the study of RVFV pathology (do Valle
et al., 2010). The inability of the MBT/Pas cells to limit
virus production is the result of several defects in the early
and late phases of the interferon (IFN) response. However,
MBT/Pas mice are able to produce type I IFNs and to
respond to them (do Valle et al., 2010). This is in contrast
with IFN (a and b) receptor 1 (Ifnar12/2)-deficient mice
that lack responsiveness to type I IFNs (Calvo-Pinilla et al.,
2009; Lorenzo et al., 2010; Boshra et al., 2011). The innate
immune response defects of MBT/Pas mice result in a
failure to control the spread of the fast-growing RVFV in
cultured cells, and are likely to contribute to the early death
of RVFV-infected MBT/Pas mice. Despite, this selective
impairment, MBT/Pas mice are able to elicit an immune
response as shown by their resistance to other viruses (do
Valle et al., 2010). Therefore, they are a good model to
assess the protective immune response to virus infections,
in particular against RVFV.
(a) (b) (c)
Fig. 1. OA3.Ts cells infected with the recom-
binant RVFV virus rCpoxNSmGn. (a) Negative
control, cells infected with the wild-type KS1. (b)
Transient expression with the positive control
pEGFP-C1 (Clontech). (c) Transient expression
with the rCpoxNSmGn 48 h after infection 10.
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Recently, the efficacy and safety of the naturally attenuated
RVFV clone 13 vaccine requiring a single injection have
been described (Dungu et al., 2010; von Teichman et al.,
2011). Development of recombinant vaccines expressing
conserved protective antigens and improving their pre-
sentation to the immune system in contrast to natural
infection would reduce the number of injections required
and still provide a cost-effective product. The aim of the
present study was to test both clone 13 and RVFV-
recombinant capripoxviruses (CPVs) as vaccines. The Gn
and Gc viral glycoproteins were selected because of
previous studies, with the objective of including the most
immunogenic and/or conserved RVFV proteins (Kakach
et al., 1988; Collett et al., 1985). Recent studies demon-
strated a significant protective immune response with
different strains of poxvirus via a cell-mediated mechanism
(Wallace & Viljoen, 2005; Wallace et al., 2006; Soi et al.,
2010; Papin et al., 2011). The expression of RVFV proteins
by the recombinant pox vector was confirmed by IFA using
the appropriate antisera. RVFV antibody and cell-mediated
immune responses to this recombinant were evaluated in
vivo via two animal experiments to evaluate the immuno-
genicity and protective immunity conferred against a
virulent RVFV challenge.
In both animal experiments, the production of RVFV
neutralizing antibodies was observed prior to the RVFV
challenge in the two groups (clone 13 and rCpoxNSmGn
RVFV) compared with the control group receiving the
recombinant capripox–HPPR. These results demonstrate
the capacity of the inbred MBT/Pas mice to elicit an
immune response against the virus and the transgenes
expressed by a CPV. These data agree with previous studies
showing that the neutralizing humoral response against the
RVFV glycoproteins and the cellular immunity induced by
the nucleoprotein protect against challenge (Lorenzo et al.,
2010; Kortekaas et al., 2010b; Mandell et al., 2010 ; Jansen
van Vuren et al., 2011).
Interestingly, in addition to the production of neutralizing
antibodies, a significant and specific increased CD4 and
CD8 lymphocyte proliferation against whole inactivated
Smithburn RVFV was observed in both vaccinated groups
confirming the immunogenicity of the vaccines. This may
indicate that the immunity induced by both candidate
vaccines (recombinant rCpoxNSmGn RVFV and clone 13)
is also cell-mediated and possibly involves CD8 cytotoxic
cells.
A protective effect of both vaccines was assessed in the
inbred wild-derived MBT/Pas mice. The survival rate
varied between 75 and 100% depending on the experiment
and the vaccine candidate. The bivalent protection against
both RVFV and CPVs challenge render the vector-based
vaccines with a significant advantage, as previously quoted
by Soi et al. (2010).
Ideally, it would be interesting to discriminate infected and
vaccinated animals (DIVA) through the development of a
companion test based on ELISAs using antigens specific to
the vaccine or to the wild-type virus. Clone 13 and the
rCpoxNSmGn RVFV constructs are convenient candidates
to provide a DIVA test since they drive the expression of a
few RVFV genes and thus vaccinated animals would lack
antibodies to other viral proteins (such as NSs for clone 13
and nucleoprotein for RVFV-Cpox), whereas these anti-
bodies are present in animals recovering from natural
infection (Fernandez et al., 2012). One of the potentials of
vector-based vaccines such as poxviruses is the ability to
include additional immunogenic genes in the construc-
tion to protect against diseases occurring in the same
Table 1. RVFV neutralizing antibody responses and protection studies for experiment 2
MBT/Pas group Individual RVFV SN
antibody titres at day 0*
Individual RVFV SN
antibody titres at day 28*
No. surviving mice/no.
challenged mice (%)
Irrelevant recombinant capripox–HPPR ,5 (6)D ,5 (6)D 0/4 (0)
rCpoxNSmGn RVFV ,5 ,5 3/4 (75)
,5 ,5
,5 5
,5 15
,5 15
,5 25
,5 30
,5 30
Clone 13 ,5 160 3/3 (100)
,5 80
,5 320
,5 160
,5 80
*Four mice at days 28 and 32 per group were killed for immunological studies.
DTotal number of mice.
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geographical area. The potential use of Cpox-vectored re-
combinant constructs as dual vaccines in hosts other than
cattle (for LSDV) is supported by the level of Cpox-
neutralizing antibodies obtained in mice. However,
challenge experiments are still required in sheep and goats
to evaluate those vaccine constructs in host species. As the
three members of the genus Capripoxvirus (SPV, goatpox
and LSDV) are closely related it is possible to use he-
terospecific viruses for inducing protection in all rumi-
nants and there is evidence that LSDV replicates in both
sheep and goats.
METHODS
Mice, viruses and cells. The MBT/Pas inbred strain was derived
from Mus musculus musculus wild progenitors trapped by F.
Bonhomme near General Toshevo in Bulgaria in 1980. The colony
has been propagated by sib-matings at the Institut Pasteur
(Bonhomme & Gue´net, 1996). Animals were housed in animal
facilities accredited by the French Ministry of Agriculture to perform
experiments on live mice, in compliance with French and European
regulations on the care and protection of the laboratory animals
(accreditation nos B 75 15-01 and B 75 15-07). All protocols included
in this study were formally approved by the Institut Pasteur animal
welfare veterinarian. Protocols were performed in compliance with
the NIH Animal Welfare Insurance #A5476-01 issued on 02/07/2007.
The RVFV clone 13 virus was produced by Ondersterpoort Biological
Products (OBP) as a virus stock in African green monkey kidney
(Vero) cells as described by Dungu et al. (2010).
The CPV strain KS1 used for vector construction was derived from a
virulent field sheep pox isolate from Kenya (0240 isolate) after two
passages in LT cells, two passages in BHK-21 (baby hamster kidney,
ATCC #CCL-10) cells and four passages in lamb kidney cells, and has
since been shown to be a strain of LSDV used as a live-attenuated
vaccine for sheep pox and goat pox in Kenya (Davies, 1976, 1981;
Kitching et al., 1987, 1989). CPV was propagated in LT cells (OA3.Ts,
ATCC CRL6546) in Dulbecco’s modified Eagle’s medium (DMEM;
Gibco) supplemented with 10% FBS as described previously (Perrin
et al., 2007).
The RVFV ZH548 strain was isolated from a human case in Egypt (El-
Akkad, 1978) and propagated in Vero cells using DMEM (Gibco)
containing 10% FBS, 2 mM L-glutamine. Virus-containing medium
was harvested when the cytopathic effect (CPE) exceeded 75%, and
the viral infectivity titre was determined by limiting dilution (Reed &
Muench, 1938).
The Smithburn vaccine was obtained from OBP.
Generation of the recombinant CPV. The complete sequence of
the M genome segment of RVFV (ZH548 strain) was cloned into
plasmid pTVT7R at the sites BbsI (Vialat et al., 1997; Johnson et al.,
2000) including the non-structural protein (NSm) and the two
glycoproteins (Gn and Gc) (GenBank accession no. Q380200). The
Gn contains three neutralizing epitopes inducing protection against a
lethal RVFV challenge (Keegan & Collett,1986; Schmaljohn et al.,
1989). Consequently, the NSmGn gene was cloned into
pKSCATpSGPT, a shuttle plasmid designed from a pBluescript II
KS backbone for homologous recombination in the CPV vector
(Berhe´ et al., 2003) under the control of the early/late synthetic
promoter (PS) from vaccinia virus (generous gift from Dr Drillien,
University of Strasbourg, France). The E. coli xanthine-guanine
phosphoribosyltransferase gene (Ecogpt), also under control of the PS
promoter, but in the opposite orientation, was used as a dominant
selectable marker to isolate the recombinants (Falkner & Moss, 1988;
Boyle & Coupar, 1988). The insertion site in the CPV genome was the
viral TK gene (Dubbs & Kit, 1964; Boyle et al., 1985; Wallace &
Viljoen, 2005). The plasmid pKSCATPSGPT-NSmGn amplified in E.
coli Top10 competent cells (Stratagene) was purified under endo-
toxin-free conditions using the Endofree Plasmid Maxi kit (Qiagen)
following the manufacturer’s instructions.
The recombinant pox virus was then generated, as illustrated in Fig. 3,
by homologous recombination after transfection of the plasmid
pKSCATPSGPT-NSmGn in OA3.Ts infected with KS-1 at an m.o.i.
of 0.1 as described previously (Berhe´ et al., 2003), but using
Lipofectamine 2000 (Invitrogen) in place of Lipofectine. After several
rounds of limiting dilution with GPT selection, standard PCR
techniques (using primers pairs) were performed to confirm the
presence of rCpoxNSmGn and the absence of the wild-type CPV KS-1.
Vaccination and challenge of mice. Two sets of experiments were
carried out in inbred MBT/Pas mice: the first set aimed at testing the
live-attenuated clone 13 as a vaccine, while the second set aimed at
testing the recombinant capripox RVF vaccine, rCpoxNSmGn. In
Fig. 2. Lymphocyte proliferation assay of vaccinated mice. PBMCs
isolated from either the irrelevant recombinant capripox–HPPR
control group, the rCpoxNSmGn RVFV group or the clone 13
group animals were stimulated with whole RVF-inactivated antigen
for 4 days. The resulting proliferation was determined by CFSE
incorporation. (a) Represents CFSE positive (%) among CD4
cells, (b) CFSE positive (%) among CD8 cells. Horizontal bars
correspond to the mean of proliferation observed for each group.
Significance was performed using the Student’s t-test. A value of
P,0.05 (*) was considered significant.
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both sets of experiments, the animals were challenged with the
virulent strain ZH548.
Experiment 1 Six-week-old MBT/Pas females (12 mice per group)
were inoculated i.p. at day 0 with either a suspension of 100 ml
containing either 104 p.f.u. of clone 13 or culture medium as a
negative control. Blood samples were collected at days 0, 21 and 28.
Thirty-one days after immunization (day 31), all animals were
challenged via the i.p. route with a suspension of 100 ml containing
100 p.f.u. of the ZH548 RVFV virulent strain. Serum for antibody
detection was collected immediately prior to immunization in six of
12 mice randomly selected and at day 28 post-immunization.
Experiment 2 Six-week-old MBT/Pas females (12 mice per group)
were individually inoculated via the i.m., i.p. and s.c. routes all
together at day 0 with a suspension of 100 ml containing 106.9 TCID50
of either the rCpoxNSmGn RVFV recombinant construct, considered
as the tested vaccine, or of a recombinant capripox–HPPR vaccine
expressing the haemagglutinin of the peste des petits ruminants virus
(PPRV) (Berhe´ et al., 2003), considered as a negative control. A
suspension of 100 ml containing 104 p.f.u. of clone 13 inoculated only
via i.p. to an additional group of 12 mice was used as a positive
control. The two groups of mice inoculated with the recombinant
CPVs were boosted 21 days post-inoculation via the same three
routes (i.m., i.p. and s.c.). Eleven days after the boost (day 32), all the
animals were challenged via the i.p. route with a suspension of 100 ml
containing 100 p.f.u. of the RVFV ZH548 virulent strain. Serum for
antibody detection was collected immediately prior to immunization
and at day 28 post-immunization. The spleens of four mice per group
were collected for the analysis of cell-mediated immunity.
IFA test. To test the expression of RVFV glycoproteins by the
recombinant CPV rCpoxNSmGn, monolayers of OA3.Ts cells were
infected and fixed after 48 h with cold acetone for 30 min at 220 uC.
Polyclonal antibodies against RVFV glycoproteins were added for
30 min at 37 uC at a dilution 1 : 400. After three PBS washes (Sigma),
cells were incubated with a 1 : 50 dilution of an anti-mouse FITC
(Dako) for 30 min at 37 uC. After three PBS final washes, readings
were performed using an inverted epifluorescence microscope
(Eclipse TE300; Nikon). Positive and negative controls were included
in the test.
Antigen-specific lymphoproliferation assays in mice. Spleens
were removed from vaccinated and challenged mice at day 33 (2 days
post-challenge) and cell suspensions were prepared as follows. Spleens
were forced through fine wire mesh and splenic erythrocytes were lysed
by osmotic treatment (170 mM Tris-buffered saline, 155 mM
ammonium chloride solution), followed by three washes in RPMI
1640 (Gibco-BRL). Cell viability was evaluated by trypan blue dye
exclusion, and cells were labelled with Cell Trace Carboxyfluorescein
Diacetate Succinimidyl Ester (CFSE; Molecular Probes). They were
then resuspended in RPMI 1640 supplemented with 10% heat-
inactivated FBS (JRH BioSciences), 50 mg gentamicin (Schering-
Plough) ml21, 2 mM glutamine (Seromed), 1% non-essential amino
acids (Seromed), 1 mM sodium pyruvate (Sigma) and 561025 M b-
mercaptoethanol (Merck) and seeded in round-bottom microtitre
plates. UV-inactivated Smithburn RVFV was added at an equivalent of
five particles per cell. Negative and positive controls for lymphopro-
liferation consisted of RPMI and Concanavalin A (ConA, 5 mg ml21;
Sigma), respectively. Lymphocytes were collected after 4 days of
incubation at 37 uC and analysed for proliferation by flow cytometry
using a FACSort and the CellQuest 3.01 software package (Becton
Dickinson). Forward (FSC) and side (SSC) scatter dot plots were used
to exclude dead cells (lower left events) and to estimate lymphoblastic
cells (upper-rightward displacement of events). In order to look at the
stimulated lymphocyte populations, cells were further PE-labelled with
anti-CD4, anti-CD8 antibodies (cat no. 553049 and 553457
respectively; Becton Dickinson) or with an isotype control (cat no.
553457; Becton Dickinson). Lymphoproliferative subpopulation cells
were estimated as events with reduced green fluorescence on an
FL16FSC dot plot and on an FL26FSC.
RVFV antibody detection by VNT. Duplicates of twofold serial
dilutions of sera in a 100 ml volume starting from 1 : 5 were added to
100 TCID50 of Smithburn RVFV (in a 50 ml volume) into 96-well
microtitre plates and incubated for 1 h at 37 uC. Then 16105 Vero
cells were added to each well and the plates were incubated at 37 uC
with 5% CO2 for 5–6 days. Titres were expressed as the inverse
highest dilutions giving 50% of CPE. Sera with titres higher than 5
were considered to be positive.
Statistical analysis. The non-parametric Mann–Whitney U test was
used to analyse differences between different T-cell subsets. A value of
P,0.05 was considered statistically significant. The non-parametric
Kruskal–Wallis test was used to compare the viral titres obtained
between the control and RVFV-Cpox or clone 13 groups with P,0.05
was considered significant.
ACKNOWLEDGEMENTS
Part of this work was facilitated through the International Network for
capacity building for the control of emerging viral vector-borne
zoonotic diseases (Arbo-Zoonet) supported by the coordination action
Fig. 3. Insertion of the RVF genes into the TK gene of the
attenuated CPV strain, KS-1. The CPV DNA insertion vector,
pKSCATpSGPT consists of the KS-1 TK gene disrupted by a
multiple cloning site (MCS) where the RVF genes have been
individually inserted [under control of the vaccinia virus (VV) early/
late synthetic promoter, PS], the E. coli gpt is a dominant
selectable marker gene (also under control of the VV promoter,
but in the opposite orientation). Arrows indicate the direction of
transcription of the VV promoters.
MBT/Pas, a relevant mouse model to test RVF vaccines
http://vir.sgmjournals.org 1461
Downloaded from www.microbiologyresearch.org by
IP:  137.108.70.7
On: Thu, 22 Dec 2016 19:16:45
project 211757 of the European Commission, the Re´gion Languedoc
Roussillon, France, the EU Network of Excellence EPIZONE (contract-
FP6-2004-Food-3-A) and the French Ministry of Foreign Affairs
(MAE) through the FSP project LABOVET 2003-24.
REFERENCES
Al-Hazmi, M., Ayoola, E. A., Abdurahman, M., Banzal, S., Ashraf, J.,
El-Bushra, A., Hazmi, A., Abdullah, M., Abbo, H. & other authors
(2003). Epidemic Rift Valley fever in Saudi Arabia: a clinical study of
severe illness in humans. Clin Infect Dis 36, 245–252.
Anderson, G. W., Jr, Slone, T. W., Jr & Peters, C. J. (1987).
Pathogenesis of Rift Valley fever virus (RVFV) in inbred rats.
Microb Pathog 2, 283–293.
Anderson, G. W., Jr, Slone, T. W., Jr & Peters, C. J. (1988). The gerbil,
Meriones unguiculatus, a model for Rift Valley fever viral enceph-
alitis. Arch Virol 102, 187–196.
Anderson, G. W., Jr, Slayter, M. V., Hall, W. & Peters, C. J. (1990).
Pathogenesis of a phleboviral infection (Punta Toro virus) in golden
Syrian hamsters. Arch Virol 114, 203–212.
Anderson, G. W., Jr, Rosebrock, J. A., Johnson, A. J., Jennings, G. B. &
Peters, C. J. (1991). Infection of inbred rat strains with Rift Valley fever
virus: development of a congenic resistant strain and observations on
age-dependence of resistance. Am J Trop Med Hyg 44, 475–480.
Berhe´, G., Minet, C., Le Goff, C., Barrett, T., Ngangnou, A., Grillet, C.,
Libeau, G., Fleming, M., Black, D. N. & Diallo, A. (2003). Development
of a dual recombinant vaccine to protect small ruminants against
peste-des-petits-ruminants virus and capripoxvirus infections. J Virol
77, 1571–1577.
Bonhomme, F. & Gue´net, J. L. (1996). The laboratory mouse and its
wild relatives. In Genetic Variants and Strains of the Laboratory Mouse,
vol. 2, pp. 1577–1596. Edited by M. F. Lyon, S. Rastan & S. D.
M. Brown. Oxford, UK: Oxford University Press.
Boshra, H., Lorenzo, G., Rodriguez, F. & Brun, A. (2011). A DNA
vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein
provides consistent immunity and protects IFNAR(-/-) mice upon
lethal virus challenge. Vaccine 29, 4469–4475.
Boyle, D. B. & Coupar, B. E. (1988). A dominant selectable marker for
the construction of recombinant poxviruses. Gene 65, 123–128.
Boyle, D. B., Coupar, B. E. & Both, G. W. (1985). Multiple-cloning-site
plasmids for the rapid construction of recombinant poxviruses. Gene
35, 169–177.
Calvo-Pinilla, E., Rodrı´guez-Calvo, T., Sevilla, N. & Ortego, J. (2009).
Heterologous prime boost vaccination with DNA and recombinant
modified vaccinia virus Ankara protects IFNAR(-/-) mice against
lethal bluetongue infection. Vaccine 28, 437–445.
Caplen, H., Peters, C. J. & Bishop, D. H. (1985). Mutagen-directed
attenuation of Rift Valley fever virus as a method for vaccine
development. J Gen Virol 66, 2271–2277.
Cleaveland, S., Laurenson, M. K. & Taylor, L. H. (2001). Diseases of
humans and their domestic mammals: pathogen characteristics, host
range and the risk of emergence. Philos Trans R Soc Lond B Biol Sci
356, 991–999.
Coetzer, J. A. (1977). The pathology of Rift Valley fever. I. Lesions
occurring in natural cases in new-born lambs. Onderstepoort J Vet Res
44, 205–211.
Coetzer, J. A. (1982). The pathology of Rift Valley fever. II. Lesions
occurring in field cases in adult cattle, calves and aborted foetuses.
Onderstepoort J Vet Res 49, 11–17.
Collett, M. S., Purchio, A. F., Keegan, K., Frazier, S., Hays, W.,
Anderson, D. K., Parker, M. D., Schmaljohn, C., Schmidt, J. &
Dalrymple, J. M. (1985). Complete nucleotide sequence of the M RNA
segment of Rift Valley fever virus. Virology 144, 228–245.
Collett, M. S., Keegan, K., Hu, S., Sridhar, P., Purchio, A. F., Ennis,
W. H. & Dalrymple, J. M. (1987). Protective subunit immunogens to
Rift Valley fever virus from bacteria and recombinant vaccinia virus.
In The Biology of Negative Strand Viruses, pp. 321–329. Edited by
B. Mahy & D. Kolakofsky. New York, NY: Elsevier.
Davies, F. G. (1976). Characteristics of a virus causing a pox disease in
sheep and goats in Kenya, with observation on the epidemiology and
control. J Hyg (Lond) 76, 163–171.
Davies, F. G. (1981). Sheep and goat pox. In Virus Diseases of Food
Animals, vol. 2, pp. 733–749. Edited by E. P. J. Gibbs. New York, NY:
Academic Press.
de Boer, S. M., Kortekaas, J., Antonis, A. F., Kant, J., van Oploo, J. L.,
Rottier, P. J., Moormann, R. J. M. & Bosch, B. J. (2010). Rift Valley
fever virus subunit vaccines confer complete protection against a
lethal virus challenge. Vaccine 28, 2330–2339.
Diallo, A., Minet, C., Berhe, G., Le Goff, C., Black, D. N., Fleming, M.,
Barrett, T., Grillet, C. & Libeau, G. (2002). Goat immune response to
capripox vaccine expressing the hemagglutinin protein of peste des
petits ruminants. Ann N Y Acad Sci 969, 88–91.
Digoutte, J. P. & Peters, C. J. (1989). General aspects of the 1987 Rift
Valley fever epidemic in Mauritania. Res Virol 140, 27–30.
do Valle, T. Z., Billecocq, A., Guillemot, L., Alberts, R., Gommet, C.,
Geffers, R., Calabrese, K., Schughart, K., Bouloy, M. & other authors
(2010). A new mouse model reveals a critical role for host innate
immunity in resistance to Rift Valley fever. J Immunol 185, 6146–6156.
Dubbs, D. R. & Kit, S. (1964). Isolation and properties of vaccinia
mutants deficient in thymidine kinase-inducing activity. Virology 22,
214–225.
Dungu, B., Louw, I., Lubisi, A., Hunter, P., von Teichman, B. F. &
Bouloy, M. (2010). Evaluation of the efficacy and safety of the Rift
Valley Fever clone 13 vaccine in sheep. Vaccine 28, 4581–4587.
Easterday, B. C. (1965). Rift Valley fever. Adv Vet Sci 10, 65–127.
El-Akkad, A. M. (1978). Rift Valley fever outbreak in Egypt. October–
December 1977. J Egypt Public Health Assoc 53, 123–128.
Elliott, R. M., Bouloy, M., Calisher, C. H., Goldbach, R., Moyer, J. T.,
Nichol, S. T., Pettersson, R. F., Plyusnin, A. & Schmaljohn, C. S.
(2000). Family Bunyaviridae. In Virus taxonomy. VIIth report of the
International Committee on Taxonomy of Viruses. pp. 599–621. Edited
by M. H. V. van Regenmortel, C. M. Fauquet, D. H. L. Bishop,
E. B. Carsten, M. K. Estes, S. M. Lemon, J. Maniloff, M. A. Mayo,
D. J. McGeoch, C. R. Pringle & R. B. Wickner. San Diego, CA:
Academic Press.
Falkner, F. G. & Moss, B. (1988). Escherichia coli gpt gene provides
dominant selection for vaccinia virus open reading frame expression
vectors. J Virol 62, 1849–1854.
Fernandez, J. C., Billecocq, A., Durand, J. P., Ceˆtre-Sossah, C.,
Cardinale, E., Marianneau, P., Pe´pin, M., Tordo, N. & Bouloy, M.
(2012). The nonstructural protein NSs induces a variable antibody
response in domestic ruminants naturally infected with Rift Valley
fever virus. Clin Vaccine Immunol 19, 5–10.
Findlay, G. M. (1932). Rift Valley fever or enzootic hepatitis. Trans R
Soc Trop Med Hyg 25, 229–265.
Findlay, G. M. & Daubney, R. J. (1931). The virus of Rift Valley fever
or enzoo¨tic hepatitis. Lancet 218, 1350–1351.
Fisher, A. F., Tesh, R. B., Tonry, J., Guzman, H., Liu, D. & Xiao, S. Y.
(2003). Induction of severe disease in hamsters by two sandfly fever
group viruses, Punta Toro and Gabek Forest (Phlebovirus,
Bunyaviridae), similar to that caused by Rift Valley fever virus. Am
J Trop Med Hyg 69, 269–276.
E. Ayari-Fakhfakh and others
1462 Journal of General Virology 93
Downloaded from www.microbiologyresearch.org by
IP:  137.108.70.7
On: Thu, 22 Dec 2016 19:16:45
Fontenille, D., Traore-Lamizana, M., Diallo, M., Thonnon, J., Digoutte,
J. P. & Zeller, H. G. (1998). New vectors of Rift Valley fever in West
Africa. Emerg Infect Dis 4, 289–293.
Gerdes, G. H. (2004). Rift Valley fever. Rev Sci Tech 23, 613–623.
Heise, M. T., Whitmore, A., Thompson, J., Parsons, M., Grobbelaar,
A. A., Kemp, A., Paweska, J. T., Madric, K., White, L. J. & other
authors (2009). An alphavirus replicon-derived candidate vaccine
against Rift Valley fever virus. Epidemiol Infect 137, 1309–1318.
Holman, D. H., Penn-Nicholson, A., Wang, D., Woraratanadharm, J.,
Harr, M. K., Luo, M., Maher, E. M., Holbrook, M. R. & Dong, J. Y.
(2009). A complex adenovirus-vectored vaccine against Rift Valley
fever virus protects mice against lethal infection in the presence of
preexisting vector immunity. Clin Vaccine Immunol 16, 1624–1632.
Ikegami, T. & Makino, S. (2009). Rift Valley fever vaccines. Vaccine 27
(Suppl. 4, ), D69–D72.
Jansen Van Vuren, P., Tiemessen, C. T. & Paweska, J. T. (2010).
Evaluation of a recombinant Rift Valley fever virus subunit
nucleocapsid protein as an immunogen in mice and sheep. The
Open Vaccine Journal. 3, 114–126.
Jansen van Vuren, P., Tiemessen, C. T. & Paweska, J. T. (2011). Anti-
nucleocapsid protein immune responses counteract pathogenic effects
of Rift Valley fever virus infection in mice. PLoS ONE 6, e25027.
Johnson, K. N., Zeddam, J. L. & Ball, L. A. (2000). Characterization and
construction of functional cDNA clones of Pariacoto virus, the first
Alphanodavirus isolated outside Australasia. J Virol 74, 5123–5132.
Kakach, L. T., Wasmoen, T. L. & Collett, M. S. (1988). Rift Valley fever
virus M segment: use of recombinant vaccinia viruses to study
Phlebovirus gene expression. J Virol 62, 826–833.
Keegan, K. & Collett, M. S. (1986). Use of bacterial expression cloning
to define the amino acid sequences of antigenic determinants on the
G2 glycoprotein of Rift Valley fever virus. J Virol 58, 263–270.
Kitching, R. P., Hammond, J. M. & Taylor, W. P. (1987). A single
vaccine for the control of capripox infection in sheep and goats. Res
Vet Sci 42, 53–60.
Kitching, R. P., Bhat, P. P. & Black, D. N. (1989). The characterization
of African strains of capripoxvirus. Epidemiol Infect 102, 335–343.
Kortekaas, J., Dekker, A., de Boer, S. M., Weerdmeester, K., Vloet,
R. P., de Wit, A. A., Peeters, B. P. & Moormann, R. J. (2010a).
Intramuscular inoculation of calves with an experimental Newcastle
disease virus-based vector vaccine elicits neutralizing antibodies
against Rift Valley fever virus. Vaccine 28, 2271–2276.
Kortekaas, J., de Boer, S. M., Kant, J., Vloet, R. P., Antonis, A. F. &
Moormann, R. J. (2010b). Rift Valley fever virus immunity provided
by a paramyxovirus vaccine vector. Vaccine 28, 4394–4401.
Lorenzo, G., Martı´n-Folgar, R., Hevia, E., Boshra, H. & Brun, A.
(2010). Protection against lethal Rift Valley fever virus (RVFV)
infection in transgenic IFNAR(-/-) mice induced by different DNA
vaccination regimens. Vaccine 28, 2937–2944.
Lovejoy, T. (2008). Climate change and biodiversity. Rev Sci Tech 27,
331–338.
Mandell, R. B. & Flick, R. (2010). Rift Valley fever virus: an
unrecognized emerging threat? Hum Vaccin 6, 597–601.
Mandell, R. B., Koukuntla, R., Mogler, L. J., Carzoli, A. K., Freiberg,
A. N., Holbrook, M. R., Martin, B. K., Staplin, W. R., Vahanian, N. N. &
other authors (2010). A replication-incompetent Rift Valley fever
vaccine: chimeric virus-like particles protect mice and rats against
lethal challenge. Virology 397, 187–198.
McIntosh, B. M., Russell, D., dos Santos, I. & Gear, J. H. (1980). Rift
Valley fever in humans in South Africa. S Afr Med J 58, 803–806.
Meegan, J. M., Hoogstraal, H. & Moussa, M. I. (1979). An epizootic of
Rift Valley fever in Egypt in 1977. Vet Rec 105, 124–125.
Mims, C. A. (1956). Rift Valley Fever virus in mice. I. General features
of the infection. Br J Exp Pathol 37, 99–109.
Morand, S. & Gue´gan, J. F. (2008). How the biodiversity sciences may
aid biological tools and ecological engineering to assess the impact of
climatic changes. Rev Sci Tech 27, 355–366.
Morrill, J. C., Mebus, C. A. & Peters, C. J. (1997). Safety of a mutagen-
attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids.
Am J Vet Res 58, 1104–1109.
Na¨slund, J., Lagerqvist, N., Habjan, M., Lundkvist, A., Evander, M.,
Ahlm, C., Weber, F. & Bucht, G. (2009). Vaccination with virus-like
particles protects mice from lethal infection of Rift Valley fever virus.
Virology 385, 409–415.
Ngichabe, C. K., Wamwayi, H. M., Barrett, T., Ndungu, E. K., Black,
D. N. & Bostock, C. J. (1997). Trial of a capripoxvirus-rinderpest
recombinant vaccine in African cattle. Epidemiol Infect 118, 63–70.
Ngichabe, C. K., Wamwayi, H. M., Ndungu, E. K., Mirangi, P. K.,
Bostock, C. J., Black, D. N. & Barrett, T. (2002). Long term immunity
in African cattle vaccinated with a recombinant capripox-rinderpest
virus vaccine. Epidemiol Infect 128, 343–349.
Papin, J. F., Verardi, P. H., Jones, L. A., Monge-Navarro, F., Brault,
A. C., Holbrook, M. R., Worthy, M. N., Freiberg, A. N. & Yilma, T. D.
(2011). Recombinant Rift Valley fever vaccines induce protective
levels of antibody in baboons and resistance to lethal challenge in
mice. Proc Natl Acad Sci U S A 108, 14926–14931.
Pastoret, P. P. (2009). Emerging diseases, zoonoses and vaccines to
control them. Vaccine 27, 6435–6438.
Perrin, A., Albina, E., Bre´ard, E., Sailleau, C., Prome´, S., Grillet, C.,
Kwiatek, O., Russo, P., Thie´ry, R. & other authors (2007).
Recombinant capripoxviruses expressing proteins of bluetongue
virus: evaluation of immune responses and protection in small
ruminants. Vaccine 25, 6774–6783.
Peters, C. J. & Anderson, J. (1981). Pathogenesis of Rift Valley fever.
Contrib Epidemiol Biostat 3, 21–41.
Peters, C. J. & Linthicum, K. J. (1994). Rift Valley Fever. In Handbook
of Zoonoses, Section B. Viral, 2nd edn, pp. 125–138. Edited by G.W. Beran
& J. H. Steele. Boca Raton, FL: CRC Press.
Reed, L. J. & Muench, H. (1938). A simple method of estimating 50%
end points. Am J Hyg 27, 493–497.
Ritter, M., Bouloy, M., Vialat, P., Janzen, C., Haller, O. & Frese, M.
(2000). Resistance to Rift Valley fever virus in Rattus norvegicus:
genetic variability within certain ‘inbred’ strains. J Gen Virol 81, 2683–
2688.
Romero, C. H., Barrett, T., Evans, S. A., Kitching, R. P., Gershon, P. D.,
Bostock, C. & Black, D. N. (1993). Single capripoxvirus recombinant
vaccine for the protection of cattle against rinderpest and lumpy skin
disease. Vaccine 11, 737–742.
Romero, C. H., Barrett, T., Kitching, R. P., Carn, V. M. & Black, D. N.
(1994). Protection of cattle against rinderpest and lumpy skin disease
with a recombinant capripoxvirus expressing the fusion protein gene
of rinderpest virus. Vet Rec 135, 152–154.
Ross, T. M., Bhardwaj, N., Bissel, S. J., Hartman, A. L. & Smith, D. R.
(2012). Animal models of Rift Valley fever virus infection. Virus Res
163, 417–423.
Saluzzo, J. F. & Smith, J. F. (1990). Use of reassortant viruses to map
attenuating and temperature-sensitive mutations of the Rift Valley
fever virus MP-12 vaccine. Vaccine 8, 369–375.
Schmaljohn, C. S., Parker, M. D., Ennis, W. H., Dalrymple, J. M.,
Collett, M. S., Slizich, J. A. & Schmaljohn, A. L. (1989). Baculovirus
expression of the M genome segment of Rift Valley fever virus and
examination of antigenic and immunogenic properties of the
expressed proteins. Virology 170, 184–192.
MBT/Pas, a relevant mouse model to test RVF vaccines
http://vir.sgmjournals.org 1463
Downloaded from www.microbiologyresearch.org by
IP:  137.108.70.7
On: Thu, 22 Dec 2016 19:16:45
Shoemaker, T., Boulianne, C., Vincent, M. J., Pezzanite, L., Al-
Qahtani, M. M., Al-Mazrou, Y., Khan, A. S., Rollin, P. E., Swanepoel,
R. & other authors (2002). Genetic analysis of viruses associated with
emergence of Rift Valley fever in Saudi Arabia and Yemen, 2000-01.
Emerg Infect Dis 8, 1415–1420.
Slingenbergh, J. I., Gilbert, M., de Balogh, K. I. & Wint, W. (2004).
Ecological sources of zoonotic diseases. Rev Sci Tech 23, 467–484.
Smith, D. R., Bird, B. H., Lewis, B., Johnston, S. C., McCarthy, S.,
Keeney, A., Botto, M., Donnelly, G., Shamblin, J. & other authors
(2012). Development of a novel nonhuman primate model for Rift
Valley fever. J Virol 86, 2109–2120.
Smithburn, K. C. (1949). Rift Valley fever: the neurotropic adaptation
of the virus and the experimental use of this modified virus as a
vaccine. Br J Exp Pathol 30, 1–16.
Soi, R. K., Rurangirwa, F. R., McGuire, T. C., Rwambo, P. M.,
DeMartini, J. C. & Crawford, T. B. (2010). Protection of sheep against
Rift Valley fever virus and sheep poxvirus with a recombinant
capripoxvirus vaccine. Clin Vaccine Immunol 17, 1842–1849.
Vialat, P., Muller, R., Vu, T. H., Prehaud, C. & Bouloy, M. (1997).
Mapping of the mutations present in the genome of the Rift Valley
fever virus attenuated MP12 strain and their putative role in
attenuation. Virus Res 52, 43–50.
Vialat, P., Billecocq, A., Kohl, A. & Bouloy, M. (2000). The S segment
of Rift Valley fever phlebovirus (Bunyaviridae) carries determinants
for attenuation and virulence in mice. J Virol 74, 1538–1543.
von Teichman, B., Engelbrecht, A., Zulu, G., Dungu, B., Pardini, A. &
Bouloy, M. (2011). Safety and efficacy of Rift Valley fever Smithburn
and clone 13 vaccines in calves. Vaccine 29, 5771–5777.
Wallace, D. B. & Viljoen, G. J. (2005). Immune responses to
recombinants of the South African vaccine strain of lumpy skin
disease virus generated by using thymidine kinase gene insertion.
Vaccine 23, 3061–3067.
Wallace, D. B., Ellis, C. E., Espach, A., Smith, S. J., Greyling, R. R. &
Viljoen, G. J. (2006). Protective immune responses induced by
different recombinant vaccine regimes to Rift Valley fever. Vaccine 24,
7181–7189.
E. Ayari-Fakhfakh and others
1464 Journal of General Virology 93
